[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE60033576D1 - Methoden zum screening knochenmorphogenetishemimetika - Google Patents

Methoden zum screening knochenmorphogenetishemimetika

Info

Publication number
DE60033576D1
DE60033576D1 DE60033576T DE60033576T DE60033576D1 DE 60033576 D1 DE60033576 D1 DE 60033576D1 DE 60033576 T DE60033576 T DE 60033576T DE 60033576 T DE60033576 T DE 60033576T DE 60033576 D1 DE60033576 D1 DE 60033576D1
Authority
DE
Germany
Prior art keywords
methods
bone morphogenetic
agents
immetics
screening bone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60033576T
Other languages
English (en)
Other versions
DE60033576T2 (de
Inventor
Dattatreymurty Bosukonda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thrasos Inc
Original Assignee
Thrasos Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thrasos Inc filed Critical Thrasos Inc
Publication of DE60033576D1 publication Critical patent/DE60033576D1/de
Application granted granted Critical
Publication of DE60033576T2 publication Critical patent/DE60033576T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
DE60033576T 2000-11-06 2000-12-07 Methoden zum screening knochenmorphogenetishemimetika Expired - Lifetime DE60033576T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24623100P 2000-11-06 2000-11-06
US246231P 2000-11-06
PCT/US2000/042657 WO2002039118A1 (en) 2000-11-06 2000-12-07 Screening methods for bone morphogenetic mimetics

Publications (2)

Publication Number Publication Date
DE60033576D1 true DE60033576D1 (de) 2007-04-05
DE60033576T2 DE60033576T2 (de) 2007-10-31

Family

ID=22929832

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60033576T Expired - Lifetime DE60033576T2 (de) 2000-11-06 2000-12-07 Methoden zum screening knochenmorphogenetishemimetika

Country Status (8)

Country Link
US (3) US20040009532A1 (de)
EP (1) EP1334365B1 (de)
AT (1) ATE354802T1 (de)
AU (1) AU2001245209A1 (de)
CA (1) CA2431552A1 (de)
DE (1) DE60033576T2 (de)
ES (1) ES2282163T3 (de)
WO (1) WO2002039118A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030185792A1 (en) * 1996-01-22 2003-10-02 Curis, Inc. Morphogen analogs of bone morphogenic proteins
US6273598B1 (en) * 1996-01-22 2001-08-14 Creative Biomolecules, Inc. Computer system and methods for producing morphogen analogs of human OP-1
AU2003215280A1 (en) 2002-02-15 2003-09-09 Northwestern University Self-assembly of peptide-amphiphile nanofibers under physiological conditions
JP4654029B2 (ja) 2002-06-17 2011-03-16 トラソス インコーポレイテッド 単一ドメインｔｄｆ関連化合物およびその類似体
US7554021B2 (en) 2002-11-12 2009-06-30 Northwestern University Composition and method for self-assembly and mineralization of peptide amphiphiles
EP2441474B1 (de) 2003-10-17 2015-08-05 Joslin Diabetes Center, Inc. Verfahren und Zusammensetzungen zur Modulation der Adipozytfunktion
CA2549164A1 (en) * 2003-12-05 2005-06-23 Northwestern University Self-assembling peptide amphiphiles and related methods for growth factor delivery
US8410246B2 (en) 2004-06-17 2013-04-02 Thrasos, Inc. TDF-related compounds and analogs thereof
EP1847265A4 (de) * 2005-01-26 2008-04-30 Mian Long Verwendung on flavonol und flavonolglykosiden zur stimulierung des wachstums renal-tubulärer epithelzellen zur sezernierung des nierensezernierenden knochenwachstumsfaktors
WO2006130690A2 (en) 2005-06-01 2006-12-07 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
AU2006292147B2 (en) 2005-09-20 2013-03-07 Thrasos Innovation, Inc. TDF-related compounds and analogs thereof
US8076295B2 (en) 2007-04-17 2011-12-13 Nanotope, Inc. Peptide amphiphiles having improved solubility and methods of using same
JP2010539932A (ja) * 2007-09-28 2010-12-24 ストライカー コーポレイション 骨形成タンパク質に対する中和抗体を検出するための方法
US8450271B2 (en) 2009-04-13 2013-05-28 Northwestern University Peptide-based scaffolds for cartilage regeneration and methods for their use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5650276A (en) * 1991-03-11 1997-07-22 Creative Biomolecules, Inc. Morphogenic protein screening method
US6071695A (en) * 1992-02-21 2000-06-06 Creative Biomolecules, Inc. Methods and products for identification of modulators of osteogenic protein-1 gene expression
US6248554B1 (en) * 1993-11-24 2001-06-19 The Procter & Gamble Company DNA sequence coding for a BMP receptor
CA2187902A1 (en) * 1994-04-29 1995-11-09 Peter Ten Dijke Morphogenic protein-specific cell surface receptors and uses therefor
AU2404695A (en) * 1994-05-04 1995-11-29 Mount Sinai Hospital Corporation Modulators of cytokines of the tgf-beta superfamily and methods for assaying for same
US6083690A (en) * 1995-06-02 2000-07-04 Osteoscreen, Inc. Methods and compositions for identifying osteogenic agents
US6190659B1 (en) * 1996-09-17 2001-02-20 The Rockefeller University Bacterial plasmin binding protein and methods of use thereof
AU4073600A (en) * 1999-04-09 2000-11-14 Human Genome Sciences, Inc. Bone morphogenic proteins

Also Published As

Publication number Publication date
EP1334365B1 (de) 2007-02-21
DE60033576T2 (de) 2007-10-31
AU2001245209A1 (en) 2002-05-21
ATE354802T1 (de) 2007-03-15
WO2002039118A1 (en) 2002-05-16
EP1334365A1 (de) 2003-08-13
US20090124537A1 (en) 2009-05-14
US20040009532A1 (en) 2004-01-15
CA2431552A1 (en) 2002-05-16
US20110081662A1 (en) 2011-04-07
ES2282163T3 (es) 2007-10-16
WO2002039118A8 (en) 2002-12-27

Similar Documents

Publication Publication Date Title
DE60131730D1 (de) Agonisten und antagonisten für den lpa-rezeptor und anwendungsmethoden
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
DE60033576D1 (de) Methoden zum screening knochenmorphogenetishemimetika
NO983431L (no) Anti-klöemidler
NO20042964L (no) Spiroazasykliske forbindelser som monoaminreseptormodulatorer
AR038563A1 (es) Composicion de ziprasidona y controles sinteticos
EP1017713A4 (de) ZYKLISCHE AGONISTEN UND ANTAGONISTEN DER C5a REZEPTOREN SOWIE G-PROTEIN GEKOPPELTEN REZEPTOREN
ATE349434T1 (de) Lactamderivaten zur verwendung als humane 11cby rezeptorantagonisten
ATE322258T1 (de) Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren
ATE288747T1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
NO20061845L (no) Fenyl-piperazinderivater som modulatorer for muskarine reseptorer
AU5301201A (en) Methods of modulating hair growth
TW200607814A (en) Cell surface receptor isoforms and methods of identifying and using the same
WO2003068944A3 (en) METHODS AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1α-
ATE273956T1 (de) Arylsubstituierte olefinische amine und ihre verwendung als cholinergische rezeptoragonisten
EA200600440A1 (ru) 4-((феноксиалкил)тио)еноксиуксусные кислоты и их аналоги
ATE309543T1 (de) Natürlicher ligand von gpcr chemr23 und dessen verwendung
WO2005117968A3 (en) Compositions and methods comprising an egfl7 antagonist for modulating vascular development
CY1105980T1 (el) Βελτιωμενη διαδικασια παρασκευης υδροβρωμικου αλατος του αλφα-πολυμορφικου ελετριπτανιου
DE69935670D1 (de) Behandlung von dyskinesie durch mu-selektive opioidantagonisten
YU17503A (sh) Receptor oblasti (ii) edb-fibronektina
DE59809283D1 (de) Inhibitoren für den urokinaserezeptor
ATE269085T1 (de) Verwendung von diltiazem zur behandlung von pathologien der netzhaut
EA200700951A1 (ru) БЕЛКИ, СОДЕРЖАЩИЕ ДОМЕНЫ vWFA И/ИЛИ ANT_IG
ATE545866T1 (de) Liganden von g-protein-gekoppelten rezeptoren und verfahren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition